Changchun High And New Technology Industries (Group) Inc(000661) technology industry (Group) Co., Ltd
Notice of independent directors on the deliberation of relevant matters at the 10th meeting of the 10th board of directors
separate opinion
As an independent director of Changchun High And New Technology Industries (Group) Inc(000661) technology industry (Group) Co., Ltd. (hereinafter referred to as “the company”), after reviewing relevant meeting materials and discussing in accordance with laws and regulations such as Shenzhen Stock Exchange Stock Listing Rules, rules for independent directors of listed companies and relevant provisions such as the articles of association and independent director system, We express our independent opinions on the relevant matters considered at the 10th meeting of the 10th board of directors of the company as follows: I. independent opinions on the financial statement report of 2021 and the profit distribution plan of 2021
We believe that the company’s 2021 financial statement truly reflects the company’s operation. The 2021 profit distribution plan takes into account the interests and reasonable demands of the majority of investors, takes into account the immediate and long-term interests of shareholders, and matches the company’s operating performance and future development. We have no objection to this proposal.
The above two proposals need to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation.
2、 Independent opinions on the proposal on renewing the employment of financial audit institutions in 2022
We believe that Daxin Certified Public Accountants (special general partnership) to be renewed by the company has sufficient independence, professional competence and investor protection ability. In providing financial audit services for the company, it has well performed the responsibilities and obligations stipulated by both parties in accordance with the independent, objective and fair practice standards, which is conducive to ensuring the quality of audit work of listed companies, It is conducive to protecting the interests of listed companies and other shareholders, especially the interests of small and medium-sized shareholders. The review procedures of this renewal comply with the relevant provisions of relevant laws and regulations. It is agreed to continue to employ Daxin Certified Public Accountants (special general partnership) as the company’s financial audit institution in 2022, and the financial audit fee is RMB 1 million.
The proposal still needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation.
3、 Independent opinions on the proposal on renewing the appointment of internal control audit institutions in 2022
We believe that Daxin Certified Public Accountants (special general partnership) to be renewed by the company has sufficient independence, professional competence and investor protection ability. In providing financial audit services for the company, it has well performed the responsibilities and obligations stipulated by both parties in accordance with the independent, objective and fair practice standards, which is conducive to ensuring the quality of audit work of listed companies, It is conducive to protecting the interests of listed companies and other shareholders, especially the interests of minority shareholders. The review procedures of this renewal comply with the relevant provisions of relevant laws and regulations. It is agreed to continue to hire Daxin Certified Public Accountants (special general partnership) as the company’s internal control audit institution in 2022, with a remuneration of RMB 250000.
The proposal still needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation.
4、 Independent opinions on self evaluation report on internal control in 2021
1. During the reporting period, the company has continuously rectified the internal control risk points found through careful sorting, and the existing internal control system is adapted to the characteristics of the company’s industry and the actual situation of business operation. The company’s internal control system complies with the basic norms of enterprise internal control, the application guidelines of enterprise internal control and the normative requirements of regulatory authorities.
2. The key activities in the company’s operation and management can implement the provisions of the company’s internal control systems, make rational use of the raised funds in accordance with various regulatory systems, and ensure that the use of the raised funds fully meets the regulatory requirements. Various internal control systems ensure the normal operation and management of the company, with rationality, integrity and effectiveness. The self-evaluation report of the company’s internal control truly and objectively reflects the construction and operation of the company’s internal control system, and there are no important and major defects.
5、 Independent opinions on matters related to capital increase of Shanghai Chun’an Biomedical Technology Co., Ltd
The investment is in line with the company’s development strategy. After this investment, we can make full use of the company’s existing molecular coupling technology platform to quickly enter the field of senile bone and joint diseases and dermatology, which is conducive to broadening the company’s business structure. The decision-making procedure of the company’s investment is legal and effective, and no damage to the interests of the company and minority shareholders is found. (there is no text on this page, which is the signature page of the opinions of independent directors on relevant matters considered at the 10th meeting of the 10th board of directors of the company) independent directors:
Li Chunhao, Zhang Chunying, Zhang Weiming
March 15, 2022
